<DOC>
	<DOC>NCT01039688</DOC>
	<brief_summary>This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.</brief_summary>
	<brief_title>Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate. Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria. Active disease as defined by both &gt;=6 tender or painful joints on motion and &gt;= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) &gt; 28 mm or a Creactive protein (CRP) concentration &gt; 7 mg/dL Blood dyscrasias including confirmed: Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; White blood cell count &lt;3.0 x 109/L; Absolute neutrophil count &lt;1.2 x 109/L; Platelet count &lt;100 x 109/L History of any other rheumatic autoimmune disease other than Sjogren's syndrome No malignancy or history of malignancy History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>oral JAK inhibitor</keyword>
	<keyword>MTX</keyword>
	<keyword>DMARD</keyword>
	<keyword>clinical trial</keyword>
	<keyword>joint diseases</keyword>
	<keyword>autoimmune diseases</keyword>
	<keyword>anti-Inflammatory agents</keyword>
	<keyword>rheumatic diseases</keyword>
</DOC>